Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases
- PMID: 2667937
- DOI: 10.2165/00003495-198937060-00003
Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases
Abstract
Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion. Therapeutic trials involving several thousands of patients with peptic ulcer disease confirm that ranitidine 300mg daily administered orally in single or divided doses is at least as effective as cimetidine 800 to 1000mg daily in increasing the rate of healing of duodenal and gastric ulcers. Similar dosages of ranitidine have been shown to relieve the symptoms of reflux oesophagitis and heal or prevent gastrointestinal damage caused by ulcerogenic drugs. Ranitidine 150mg orally at night maintains ulcer healing in the long term. Ranitidine has also demonstrated good results in the treatment of Zollinger-Ellison syndrome and in the prevention of aspiration pneumonitis when given prior to surgery and to pregnant women at full term. It may also have a place in the management of acute upper gastrointestinal bleeding and in the prevention of stress ulcers in the intensive care setting, although these areas require further investigation. Ranitidine has been used safely in obstetric patients during labour, in children, the elderly, and in patients with renal impairment when given in appropriate dosages. The drug is very well tolerated and is only infrequently associated with serious adverse reactions or clinically significant drug interactions. Even at high dosages, ranitidine appears devoid of antiandrogenic effects. Ranitidine is clearly comparable or superior to most other antiulcer agents in the treatment and prevention of a variety of gastrointestinal disorders associated with gastric acid secretion. With its favourable efficacy and tolerability profiles, ranitidine must be considered a first-line agent when suppression of gastric acid secretion is indicated.
Similar articles
-
Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005. Drugs. 1989. PMID: 2573505 Review.
-
Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.Drugs. 1986 Jul;32(1):15-47. doi: 10.2165/00003495-198632010-00002. Drugs. 1986. PMID: 3527658 Review.
-
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.Drugs. 1992 Aug;44(2):225-50. doi: 10.2165/00003495-199244020-00007. Drugs. 1992. PMID: 1382017 Review.
-
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.Drugs. 1986 Sep;32(3):197-221. doi: 10.2165/00003495-198632030-00001. Drugs. 1986. PMID: 2875864 Review.
-
Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.Drugs. 1982 Oct;24(4):267-303. doi: 10.2165/00003495-198224040-00002. Drugs. 1982. PMID: 6128216 Review.
Cited by
-
Preparation and In Vitro Evaluation of a Stomach Specific Drug Delivery System based on Superporous Hydrogel Composite.Indian J Pharm Sci. 2011 Jan;73(1):30-7. doi: 10.4103/0250-474X.89754. Indian J Pharm Sci. 2011. PMID: 22131619 Free PMC article.
-
Site-dependent small intestinal absorption of ranitidine.Eur J Clin Pharmacol. 1994;46(3):253-9. doi: 10.1007/BF00192558. Eur J Clin Pharmacol. 1994. PMID: 8070507
-
Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities.Pharm Res. 1998 Jan;15(1):47-52. doi: 10.1023/a:1011992518592. Pharm Res. 1998. PMID: 9487545
-
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002. Clin Pharmacokinet. 1990. PMID: 2199130 Review.
-
Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.Drugs. 1991 Jul;42(1):138-70. doi: 10.2165/00003495-199142010-00008. Drugs. 1991. PMID: 1718683 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical